JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB237750

Recombinant EBV gp340/220 Envelope Protein (Tagged)

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant EBV gp340/220 Envelope Protein (Tagged) is a Epstein-Barr Virus (Strain B95-8) Fragment protein, in the 1 to 493 aa range, expressed in Escherichia coli, with >90%, suitable for SDS-PAGE, Mass Spec.

View Alternative Names

Envelope glycoprotein GP350, Membrane antigen, MA, BLLF1, BLLF1a, Envelope glycoprotein GP340/220, Envelope glycoprotein GP340/GP220, Envelope glycoprotein Gp220/340, Epstein Barr Virus envelope glycoprotein complex 250/350, Epstein Barr gp350 envelope protein, Epstein Barr virus, MA, Membrane antigen

3 Images
Mass Spectrometry - Recombinant EBV gp340/220 Envelope Protein (Tagged) (AB237750)
  • Mass Spec

Unknown

Mass Spectrometry - Recombinant EBV gp340/220 Envelope Protein (Tagged) (AB237750)

Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of ab237750 could indicate that this peptide derived from E.coli-expressed Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4) gp340/220 Envelope Protein.

Mass Spectrometry - Recombinant EBV gp340/220 Envelope Protein (Tagged) (AB237750)
  • Mass Spec

Supplier Data

Mass Spectrometry - Recombinant EBV gp340/220 Envelope Protein (Tagged) (AB237750)

Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of ab237750 could indicate that this peptide derived from E.coli-expressed Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4) gp340/220 Envelope Protein.

SDS-PAGE - Recombinant EBV gp340/220 Envelope Protein (Tagged) (AB237750)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant EBV gp340/220 Envelope Protein (Tagged) (AB237750)

(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) analysis with 5% enrichment gel and 15% separation gel of ab237750.

Key facts

Purity

>90% SDS-PAGE

Expression system

Escherichia coli

Tags

6x His tag N-Terminus SUMO tag N-Terminus

Applications

Mass Spec, SDS-PAGE

applications

Biologically active

No

Accession

P03200

Animal free

No

Carrier free

No

Species

Epstein-Barr Virus (Strain B95-8)

Storage buffer

pH: 7.2 - 7.4 Constituents: Tris buffer, 50% Glycerol (glycerin, glycerine)

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "Mass Spec": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Sequence info

[{"sequence":"MEAALLVCQYTIQSLIHLTGEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQLDLDFGQLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINVTTGEEQQVSLESVDVYFQDVFGTMWCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLDVTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVPSGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCIQSNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTETDFKCKWTLTSGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVIFSKAPESTTTSPTLNTTGFADPNTTTGLPSSTHVPTNLTAPASTGPTVSTADVTSPTPAGTTSGASPVTPSPS","proteinLength":"Fragment","predictedMolecularWeight":"68.5 kDa","actualMolecularWeight":null,"aminoAcidEnd":493,"aminoAcidStart":1,"nature":"Recombinant","expressionSystem":"Escherichia coli","accessionNumber":"P03200","tags":[{"tag":"6x His","terminus":"N-Terminus"},{"tag":"SUMO","terminus":"N-Terminus"}]}]

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Avoid freeze / thaw cycle
False

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The EBV gp340/220 Envelope Protein also known as the Epstein-Barr virus major glycoprotein gp350/220 plays an important role in the viral entry mechanism. It is approximately 340 kDa in mass and is expressed on the surface of the Epstein-Barr virus (EBV) particles. This glycoprotein mediates the attachment of virions to host cells by binding to the complement receptor type 2 (CR2/CD21) on B lymphocytes which facilitates the viral entry into the host cell. The expression of gp340/220 is restricted to EBV-infected cells and encapsulates the virus playing an integral role in its infectivity.
Biological function summary

This glycoprotein promotes viral entry by enhancing the fusion between the viral envelope and the host cell membrane. It is an important component of the viral entry machinery acting in conjunction with other viral proteins such as gp42 to initiate infection. It functions as part of a greater complex that mediates the initial stages of infection enabling the virus to establish itself in resting B cells and epithelial cells. By allowing the attachment and initial colonization of host cells EBV gp340/220 serves as an important facilitator of EBV's life cycle.

Pathways

EBV gp340/220 plays a substantial role in the viral infection process and influences pathways like the complement pathway and B cell activation pathway. It interacts prominently with CD21 a receptor on B cells to trigger the internalization of the virus. This interaction forms a basis for activating signaling pathways inside the host cell subsequently leading to events that promote viral replication and latent infection. Although gp350/220 remains distinct its functions influence other viral proteins such as LMP1 in downstream signaling pathways which contribute to virus persistence and oncogenesis.

EBV gp340/220 is closely linked to infectious mononucleosis and Burkitt's lymphoma. It initiates infection which may culminate in persistent latent infections contributing to the development of these conditions. In infectious mononucleosis this glycoprotein participates in binding to CR2/CD21 facilitating viral entry and causing the characteristic symptoms of the disease. In Burkitt’s lymphoma disturbances in pathways associated with EBV gp340/220 and LMP1 have been implicated in tumorigenesis illustrating the connection between the viral protein and disease progression.

Specifications

Form

Liquid

General info

Function

Initiates virion attachment to host B-lymphocyte cell, leading to virus entry. Acts by binding to host CR2 at the surface of B-lymphocytes, facilitating the binding of viral glycoprotein gp42 to HLA class II molecules. Attachment triggers virion-host membrane fusion and invasion of the host cell.

Sequence similarities

Belongs to the Epstein-Barr GP350 family.

Post-translational modifications

Extensively glycosylated.

Product protocols

Target data

Initiates virion attachment to host B-lymphocyte cell, leading to virus entry. Acts by binding to host CR2 at the surface of B-lymphocytes, facilitating the binding of viral glycoprotein gp42 to HLA class II molecules. Attachment triggers virion-host membrane fusion and invasion of the host cell.
See full target information BLLF1

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com